AFM
MTNB icon

Anson Funds Management’s Matinas BioPharma MTNB Stock Holding History

Anson Funds Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-71,680
Closed -$3.76M – 308
2021
Q1 		$3.76M Buy
+71,680
New +$4.81M 0.45% 59

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Anson Funds Management's MTNB Position: Q2 2021 in Review

Anson Funds Management sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 71,680 shares — an estimated $3.76M sold.

Anson Funds Management first reported a position in MTNB in Q1 2021 and held it in 1 quarter. The position peaked at $3.76M in Q1 2021. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • Anson Funds Management reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • Anson Funds Management sold 71,680 Matinas BioPharma shares in Q2 2021, an estimated $3.76M.
  • Anson Funds Management first reported a position in Matinas BioPharma in Q1 2021 and held it in 1 quarter.
  • Anson Funds Management's Matinas BioPharma position peaked at $3.76M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Anson Funds Management's 13F filing for Q2 2021, filed 13 Aug 2021.